FDA Takes Hard Line On Opioid Class REMS: Cooperate, Or Face Withdrawal

FDA appears to be taking a hard line with drug sponsors on the development of a Risk Evaluation and Mitigation Strategy for extended-release opioids: cooperate on a class REMS, or face a product withdrawal